To include your compound in the COVID-19 Resource Center, submit it here.

Daiichi and MD Anderson partner to develop AML candidates

Daiichi Sankyo Co. Ltd. (Tokyo:4568) and the University of Texas MD Anderson Cancer Center (Houston, Texas) partnered to

Read the full 182 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE